Regeneron shares edge higher as second quarter earnings surpass estimates

Published 01/08/2025, 12:22
© Reuters

Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus estimate. Revenue also beat forecasts, coming in at $3.68 billion versus the expected $3.28 billion.

The biopharmaceutical company’s total revenue increased 4% YoY, driven by strong performance across several key products. Dupixent global net sales, recorded by Sanofi (NASDAQ:SNY), grew 22% to $4.34 billion, while EYLEA HD U.S. net sales jumped 29% to $393 million. However, combined EYLEA HD and EYLEA U.S. net sales decreased 25% to $1.15 billion.

The stock is up 0.3% following the results.

"Regeneron (NASDAQ:REGN) had a strong quarter, marked by significant growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo along with multiple regulatory approvals," said Leonard Schleifer, Chief Executive Officer of Regeneron.

The company reported several regulatory achievements during the quarter, including FDA approval for Lynozyfic for relapsed or refractory multiple myeloma and Dupixent approvals for bullous pemphigoid and chronic spontaneous urticaria. The FDA also accepted for priority review Libtayo’s application for adjuvant cutaneous squamous cell carcinoma.

Regeneron updated its financial guidance for 2025, adjusting its R&D and SG&A expense projections. The company now expects non-GAAP R&D expenses of $5.1-$5.2 billion and non-GAAP SG&A expenses of $2.45-$2.55 billion.

During the quarter, Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends. The company’s board declared a cash dividend of $0.88 per share, payable on September 3, 2025.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.